Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure

scientific article published on 06 March 2019

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/EJHF.1437
P698PubMed publication ID30843353

P50authorNicolas GirerdQ56394664
Leong L NgQ61120317
Adriaan A VoorsQ91537232
Joachim StruckQ91631606
Biniyam G DemisseiQ91665607
Stefan D AnkerQ93002591
Jozine M Ter MaatenQ114321777
Daan KremerQ114429154
Nilesh SamaniQ19665717
Marco MetraQ39274051
Chim C. LangQ41297830
Kenneth DicksteinQ43248428
P2093author name stringAndreas Bergmann
John Cleland
Dirk J van Veldhuisen
Simon P R Romaine
P2860cites workIncreased plasma levels of adrenomedullin in patients with heart failureQ71827359
Elevation of Circulating and Ventricular Adrenomedullin in Human Congestive Heart FailureQ71955928
Differential responses of circulating and tissue adrenomedullin and gene expression to volume overloadQ74044863
Tackling Early Heart Failure Deaths and Readmissions by Estimating CongestionQ86635582
Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failureQ89186716
Adrenomedullin in heart failure: pathophysiology and therapeutic applicationQ90789256
Sandwich Immunoassay for Bioactive Plasma AdrenomedullinQ97416560
Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis.Q33750991
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with theQ34640762
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribQ34677347
Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failureQ36578779
Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shockQ38382864
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart FailureQ38391668
Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic EmQ38496703
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European studyQ40280356
Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failureQ40313672
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.Q40777024
FGF23 regulates renal sodium handling and blood pressureQ42952198
Vascular endothelial adrenomedullin-RAMP2 system is essential for vascular integrity and organ homeostasisQ43639160
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trialQ44622051
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.Q48741780
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failureQ48742018
Integrative Assessment of Congestion in Heart Failure Throughout the Patient JourneyQ49954448
Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and SepsisQ50086305
Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in SepsisQ50086313
Adrenomedullin and endothelial barrier function.Q52922207
Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin.Q54125748
P433issue6
P304page(s)732-743
P577publication date2019-03-06
P1433published inEuropean Journal of Heart FailureQ5017954
P1476titleBio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure
P478volume21

Reverse relations

cites work (P2860)
Q92099993Adrenomedullin, a circulating biomarker of congestion: in search of evidence
Q93332917April 2020 at a glance: epidemiology, prevention, and biomarkers
Q96585882Bioactive adrenomedullin in plasma is associated to biventricular filling pressures in patients with advanced heart failure
Q91631616Circulating Biologically Active Adrenomedullin Predicts Organ Failure and Mortality in Sepsis
Q91662964Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission
Q94948551Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Q90022431Fibroblast growth factor 23 and the quest for the Holy Grail in heart failure: will the Crusaders be forced to surrender?
Q104074195Heart failure in the last year: progress and perspective
Q89459313Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
Q92925805June 2019 at a glance: from genetics to haemodynamics, biomarkers and imaging for the prediction of outcomes

Search more.